Company Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer’s disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage.
The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS.
The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997.
ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1993 |
| IPO Date | May 27, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 654 |
| CEO | Catherine Owen Adams |
Contact Details
Address: 12830 El Camino Real, Suite 400 San Diego, California 92130 United States | |
| Phone | 858 558 2871 |
| Website | acadia.com |
Stock Details
| Ticker Symbol | ACAD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001070494 |
| CUSIP Number | 004225108 |
| ISIN Number | US0042251084 |
| Employer ID | 06-1376651 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Catherine E. Owen Adams | Chief Executive Officer and Director |
| Mark C. Schneyer | Executive Vice President and Chief Financial Officer |
| Stephen R. Davis J.D. | Consultant |
| Dr. Elizabeth H.Z. Thompson Ph.D. | Head of Research and Development |
| Jennifer J. Rhodes J.D. | Chief Legal Officer and Secretary |
| Rob Ackles | Chief People Officer |
| James K. Kihara | Senior Vice President of Finance |
| Dr. Kevin R. Oliver Ph.D. | Chief Business Officer |
| Thomas Andrew Garner | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 144 | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Dec 11, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |